Skip to content

Praxis Precision Medicines

US · PRAX #1645 by market cap Listed 2020
300.43 -10.47 -3.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 311.66 +0.24%
After-hours 300.43 0.00%
Overnight 315.00 +1.32%
386.33239.02300.432026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on PRAX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +32.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 15.1% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -2,340.3% Better than 2%
Net margin -2,137.5% Better than 2%
Return on equity -45.8% Better than 10%
Return on invested capital -45.8% Better than 6%
Momentum B-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -20.1% Better than 31%
6-month return -12.6% Better than 36%
12-month return (ex latest month) 49.0% Better than 83%
Distance below 52-week high 23.5% Better than 53%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 10.2x Better than 94%
Debt to assets 0.0% Better than 99%
Interest coverage -206.9x Better than 4%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 91.7% Better than 75%
Upside to average target 142.4% Better than 90%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -8.44%
1M +13.59%
3M -17.60%
6M -10.48%
YTD +1.93%
1Y +83.09%
3Y +1,528.35%
5Y +7.28%

Key statistics

Price & volume

Prev close
310.90
Open
310.07
Day range
298.54 - 314.15
Avg price
304.90
Volume
806.16K
Turnover
245.80M
Amplitude
5.02%
52-week range
167.32 - 392.70

Valuation

P/E
-22.29
P/E (TTM)
-23.43
P/B
6.67
EPS
-13.48
Net profit
-376.79M
Net assets
1.26B

Share structure

Market cap
8.40B
Float cap
7.24B
Shares out
27.95M
Float shares
24.11M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-10-16
52-week range 59% of range
167.32 392.70

23.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+11.79M net over the window

Short interest

Shares short
4.21M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Praxis Precision Medicines (PRAX)?

Praxis Precision Medicines last traded at 300.43. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Praxis Precision Medicines's market cap?

About 8.40B.

What is the P/E ratio of Praxis Precision Medicines?

The trailing twelve-month P/E is -23.43. The Valuation tab shows it against the stock's own five-year range.

Does Praxis Precision Medicines pay a dividend?

Praxis Precision Medicines does not currently pay a regular dividend.

Is Praxis Precision Medicines a buy according to analysts?

The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 728.33, which implies 142.4% upside from the current price. This is not investment advice.

What is Praxis Precision Medicines's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Praxis Precision Medicines a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:15 · For reference only, not investment advice and not tailored to your situation.

Praxis Precision Medicines discussion 0 comments

Add a comment